Adherence and outcomes of patients prescribed dabigatran (Pradaxa) in routine clinical practice

Internal Medicine Journal

Volumn 44, Issue 3, 2014, Pages 261-265

  Thorne, K ^a   Jayathissa, S ^c   Dee, S ^c   Briggs, N ^a   Taylor, J ^a   Reid, S ^d   De Silva, K ^e   Dean, J ^b  

^a CAPITAL AND COAST DISTRICT HEALTH BOARD   (New Zealand)

^b Cardiology Department   (New Zealand)

^c Hutt Valley District Health Board   (New Zealand)

^d Ropata Medical Centre   (New Zealand)

^e NaeNae Medical Centre   (New Zealand)

Author keywords

Anticoagulant; Atrial fibrillation; Compliance; Complication; Epidemiology

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; DABIGATRAN; DABIGATRAN ETEXILATE; ENOXAPARIN; WARFARIN; ANTITHROMBIN; BENZIMIDAZOLE DERIVATIVE; BETA ALANINE;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CLINICAL PRACTICE; CONTROLLED STUDY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL SYMPTOM; HEARTBURN; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; NEW ZEALAND; OBSERVATIONAL STUDY; PATIENT COMPLIANCE; PNEUMONIA; PRACTICE GUIDELINE; PRESCRIPTION; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUESTIONNAIRE; TREATMENT DURATION; TREATMENT OUTCOME; VERY ELDERLY; ANALOGS AND DERIVATIVES; CHEMICALLY INDUCED; CLINICAL TRIAL; COHORT ANALYSIS; FOLLOW UP; GASTROINTESTINAL DISEASES; MIDDLE AGED; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL;

AGED; AGED, 80 AND OVER; ANTITHROMBINS; BENZIMIDAZOLES; BETA-ALANINE; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; GASTROINTESTINAL DISEASES; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 84896857314     PISSN: 14440903     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/imj.12370     Document Type: Article

References (8)

1. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboomz J, Oldgrenz J, Parekhz A etal. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-1151.
2. European Medicines Agency updates on safety of Pradaxa. [cited 2013 May 1]. Available from URL: http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2011/11/news_detail_001390.jsp&mid=WC0b01ac058004d5c1&jsenabled=true
3. FDA Drug Safety Communication: update on the risk for serious bleeding events with the anticoagulant Pradaxa. [cited 2013 May 1]. Available from URL: http://www.fda.gov/Drugs/DrugSafety/ucm326580.htm
4. Attia JR, Pearce R. The use, misuse and abuse of dabigatran. Med J Aust 2013; 198: 356-357.
5. Eikelboom JW, Hankey GJ. Is there really misuse and abuse of dabigatran? Med J Aust 2013; 198: 358-359.
6. 'Game changing' anti-clotting treatment funded. Pharmac. Media Release. [cited 2012 Dec 1]. Available from URL: http://www.pharmac.govt.nz/2011/06/14/Dabigatran%20funded.pdf
7. Harper P, Young L, Merriman E. Bleeding risk with dabigatran in the frail elderly. N Engl J Med 2012; 366: 864-866.
8. Best Practice Advocacy Centre (BPAC). The use of dabigatran in general practice: a cautious approach is recommended. BPJ 2011; 38: 10-27.